Elinzanetant Patent Expiration

Elinzanetant was first introduced by Bayer Healthcare Pharmaceuticals Inc in its drug Lynkuet on Oct 24, 2025.


Elinzanetant Patents

Given below is the list of patents protecting Elinzanetant, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Lynkuet US12533358 May 14, 2045 Bayer Hlthcare
Lynkuet US10774091 Soft Gelatin Capsule Formulation Mar 13, 2039 Bayer Hlthcare
Lynkuet US11787820 Method Of Treating Certain Sex Hormone-Dependent Diseases Administering A Soft Gelatin Capsule Comprising Nk1 And Nk3 Receptors Antagonists Mar 13, 2039 Bayer Hlthcare
Lynkuet US12264164 Method Of Treatment Of Symptoms Of Menopause Mar 13, 2039 Bayer Hlthcare
Lynkuet US10195205 Uses Of Dual Nk1/Nk3 Receptor Antagonists For Treating Sex-Hormone Diseases May 18, 2036 Bayer Hlthcare
Lynkuet US7683056 Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders Sep 15, 2026 Bayer Hlthcare



Elinzanetant's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Elinzanetant Generic API Manufacturers

Given below is the list of companies who have filed for Elinzanetant generic, along with the locations of their manufacturing plants worldwide.